AE Wealth Management LLC Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AE Wealth Management LLC bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the second quarter, Holdings Channel reports. The institutional investor bought 2,533 shares of the specialty pharmaceutical company’s stock, valued at approximately $270,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Kovack Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 88.8% in the 1st quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after acquiring an additional 26,628 shares during the last quarter. John G Ullman & Associates Inc. purchased a new stake in Jazz Pharmaceuticals during the first quarter valued at about $3,631,000. Swedbank AB bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at about $106,936,000. Vanguard Group Inc. lifted its stake in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after acquiring an additional 84,941 shares during the last quarter. Finally, APG Asset Management US Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $1,389,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $173.07.

Insider Activity

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.7 %

NASDAQ JAZZ opened at $110.93 on Friday. The stock’s 50 day moving average is $111.02 and its 200 day moving average is $110.82. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm has a market capitalization of $7.00 billion, a PE ratio of 22.87, a P/E/G ratio of 1.36 and a beta of 0.57. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Research analysts forecast that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.